Blog

The latest move to save Intel is the appointment of Lip-Bu Tan as the new CEO. With this change, the company is trying to stabilize after years of losses, as well as a decline in market share. Lip-Bu Tan will take the lead at a time when Intel is facing existential challenges, especially in artificial intelligence (AI) and chip manufacturing. Following the news, Intel's share price rose 15%, indicating a positive perception of this fundamental momentum by the market.*

The year 2024 was turbulent for the European automotive industry, leading to declines in corporate profitability and outlooks suggesting that the situation is unlikely to improve anytime soon. One such case is the German luxury car manufacturer Porsche. Although the company reported strong financial results, last year was marked by a downturn. In addition to challenges in Europe, it also faced a drop in demand in China. Despite this, Porsche is striving to sustain and revive its business by implementing measures such as strategic cost management.

Earnings season continues, with another company surpassing analyst estimates: tech giant Broadcom Inc. A key factor in its growth was revenue from the artificial intelligence (AI) segment, along with strong results from its software division. Given the nearly 30% drop in its stock price, these results are even more significant as they have the potential to restore the growth trend, giving investors the opportunity to buy at a more favourable valuation.*

One of the most popular companies on Wall Street, Nvidia, released its earnings on Wednesday, February 26, 2025, confirming impressive growth in the AI chip segment. Despite this, its stock faced pressure due to expectations of a decline in gross margin, which created uncertainty among investors. However, the positive news is that Nvidia has secured enough manufacturing capacity for this year with its main supplier, TSMC. Yet, it faces the risk of new tariffs imposed by the US government.

Pharmaceutical giant Eli Lilly has made a significant shift in its pricing strategy for the popular weight-loss drug Zepbound. The company announced that selected doses would be available at a lower price to help patients without adequate health insurance while strengthening its market position. This move comes at a time when regulatory authorities have declared the end of the drug shortage, and Eli Lilly faces growing competition. Additionally, the company is investing heavily in developing an oral alternative, which could significantly reshape the market.